Register
Adjuvant pembrolizumab therapy reduces recurrence risk in stage III melanoma |
Journal Updates
eMediNexus Coverage from: 
Adjuvant pembrolizumab therapy reduces recurrence risk in stage III melanoma
eMediNexus,  16 April 2018
remove_red_eye 613 Views
#Dermatology #Hematology #Oncology #Pathology and Lab Medicine #Pharmacist

0 Read Comments                

Adjuvant therapy with pembrolizumab (Keytruda) 200 mg every 3 weeks for up to 1 year in patients with high-risk stage III melanoma reduced the risk of recurrence or death by 43% with no new toxic effects identified, as per results from the phase III EORTC 1325-MG/KEYNOTE-054 trial published April 15, 2018 in the New England Journal of Medicine.


Comments

Comments on eMediNexus are moderated. We retain the right to remove any comments at our sole discretion.